

**AKR7L Blocking Peptide (Center)**  
**Synthetic peptide**  
**Catalog # BP21480c****Specification**

---

**AKR7L Blocking Peptide (Center) - Product Information**

Primary Accession [Q8NHP1](#)

**AKR7L Blocking Peptide (Center) - Additional Information**

**Gene ID** 246181

**Other Names**

Aflatoxin B1 aldehyde reductase member 4, 1---, AFB1 aldehyde reductase 3, AFB1-AR 3, Aldoketoreductase 7-like, AKR7L, AFAR3, AKR7A4

**Target/Specificity**

The synthetic peptide sequence is selected from aa 207-217 of HUMAN AKR7L

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**AKR7L Blocking Peptide (Center) - Protein Information**

**Name** AKR7L

**Synonyms** AFAR3 {ECO:0000303|PubMed:12879023}, AKR

**Function**

Can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol. May be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen (By similarity).

**Tissue Location**

Mainly expressed in uterus.

**AKR7L Blocking Peptide (Center) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

#### **AKR7L Blocking Peptide (Center) - Images**

#### **AKR7L Blocking Peptide (Center) - Background**

Can reduce the dialdehyde protein-binding form of aflatoxin B1 (AFB1) to the non-binding AFB1 dialcohol. May be involved in protection of liver against the toxic and carcinogenic effects of AFB1, a potent hepatocarcinogen (By similarity).

#### **AKR7L Blocking Peptide (Center) - References**

Gregory S.G.,et al.Nature 441:315-321(2006).  
Praml C.,et al.Oncogene 22:4765-4773(2003).